Merck pours $400M into flea drugs for Fido; Avrobio shows durability; Rhythm gets priority review
→ Merck has found its newest $400 million, just don’t expect to ever personally receive a drug from it. The NJ-based pharma giant has acquired Sentinel, a maker of drugs that protect dogs and other companion animals from ticks, fleas and other parasites. Merck already makes a line of pet anti-parasitics called Bravecto. “These products will target different parts of the flea lifecycle and will offer broad-spectrum, internal parasite protection in the SENTINEL brand and the extended duration flea and tick protection of BRAVECTO,” Rick DeLuca, president of Merck Animal Health said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
